Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents

A. Gonelli, C. Mischiati, R. Guerrini, R. Voltan, S. Salvadori, Giorgo Zauli

Research output: Contribution to journalArticlepeer-review


Although the role of serine/threonine protein kinase C (PKC) in malignant transformation is known from decades, an anti-PKC based approach in cancer therapy was hampered for the difficulties in developing pharmacological compounds able to selectively inhibit specific PKC isoforms. In this review, the role of PKC-ε and PKC-δ in promoting and counteracting tumor progression in different types of cancer, respectively, will be discussed in relationship with promising therapeutic perspectives based either on small molecule inhibitors or on natural compounds. Among a miriad of molecules able to modulate PKC activity, we will focus on the role of the enzastaurin and briostatin-1, which already entered clinical trials for several human cancers.

Original languageEnglish
Pages (from-to)498-509
Number of pages12
JournalMini-Reviews in Medicinal Chemistry
Issue number4
Publication statusPublished - 2009


  • Apoptosis
  • Differentiation
  • PKC
  • Tumorigenesis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents'. Together they form a unique fingerprint.

Cite this